1. Oncological monitoring after transanal total mesorectal excision (TaTME) for rectal neoplasia.
- Author
-
Sanchon, L., Bardaji, M., Labro, M., Curto, J., Soto, C., Puig, A., Pastor, J. C., Gómez, C., Osorio, A., Guariglia, C., Pardo, S., Vidal, C., and Collera, P.
- Subjects
OVERALL survival ,TUMORS ,PROGRESSION-free survival ,DISEASE progression ,OPERATIVE surgery - Abstract
Background: The surgical treatment of choice for rectal neoplasia is total mesorectal excision (TME). The transanal approach enables a better approach in male and obese patients and/or those with a narrow pelvis and in patients with small tumors. Short-term results are comparable with those for laparoscopy or the open approach, but the medium- and long-term oncological data are sparse. The aim of the present study was to evaluate our early experience with transanal TME (TaTME). Methods: This was a retrospective study conducted on patients who underwent TaTME at our center between August 2013 and April 2017 with a follow-up ≥ 3 years. Histopathology, complications, mortality, neoplastic recurrence and disease-free survival were analyzed. Results: One hundred patients (68 men and 32 women,, median age 66.8 years [range 29.6–91.2 years]) were included. There were 67 T3 cases (67%) with 74 N0 cases (74%), the mesorectal quality was graded optimal for 87.6% and only 2 cases of radial margin involvement were detected (2%). The median follow-up period was 47.6 months (range 11.8–78.9 months). Eighteen cases of recurrence were diagnosed, of which 3 (3%) recurred locally with an average disease-free period of 43.1 months. Overall survival was 80% and mortality due to progression of disease was 13%. Conclusions: TaTME is a safe surgical procedure with surgical, anatomopathological and oncological results at 3 years (medium-term) comparable with those for the laparoscopic and open approaches. Better monitoring is required with studies of the long-term functional and quality of life outcomes, i.e., at 5 or 10 years. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF